NASDAQ · ORGO
Organogenesis Holdings Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ORGO: Nov 05, 2026
Organogenesis Holdings Inc. Class A Common Stock is expected to report earnings on 11/05/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. The reported EPS for the same quarter last year was $0.18.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · MarketBeat · RTTNews · Fintel- The Motley Fool · Aug 13, 7:46 PM EDTOrganogenesis (ORGO) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 7, 3:04 AM EDTOrganogenesis Q2 Earnings Call HighlightsOrganogenesis (NASDAQ:ORGO) reported a sharp year-over-year decline in second-quarter revenue as the skin substitute market continued to adjust to coverage and payment changes from the Centers for Medicare & Medicaid Services, while management pointed to sequential improvement in
- RTTNews · Jul 28, 6:51 AM EDTOrganogenesis Publishes Positive RCT Data For Affinity Graft In Treating Venous Leg Ulcers(RTTNews) – Organogenesis Holdings Inc. (ORGO), a regenerative medicine company, on Tuesday announced the publication of results from a randomized control trial of Affinity technology in treating complex venous leg ulcers (VLUs) when compared to standard-of-care treatments. The r
- RTTNews · Jul 7, 12:41 AM EDTOrganogenesis Secures FDA Review For ReNu In Knee Osteoarthritis(RTTNews) – Organogenesis Holdings Inc. (ORGO) announced that the U.S. FDA has accepted its Biologics License Application (BLA) for ReNu, a cryopreserved amniotic suspension allograft designed to manage pain in patients with symptomatic knee osteoarthritis.
- Fintel · May 28, 5:09 PM EDTTruist Securities Initiates Coverage of Organogenesis Holdings (ORGO) with Hold RecommendationFintel reports that on May 28, 2026, Truist Securities initiated coverage of Organogenesis Holdings (NasdaqCM:ORGO) with a Hold recommendation. Analyst Price Forecast Suggests 206.77% Upside
- The Motley Fool · May 8, 1:28 PM EDTOrganogenesis (ORGO) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · May 8, 8:07 AM EDTOrganogenesis Q1 Earnings Call HighlightsOrganogenesis (NASDAQ:ORGO) reported a sharp year-over-year revenue decline in the first quarter of 2026, with executives pointing to significant disruption in the skin substitute market following Medicare policy changes and related commentary from the Centers for Medicare & Medi
- RTTNews · Apr 28, 10:30 PM EDTOrganogenesis Completed Rolling BLA Submission For ReNu For Knee Osteoarthritis(RTTNews) – Organogenesis Holdings Inc. (ORGO) has completed its rolling BLA submission to the U.S. FDA for ReNu, a cryopreserved amniotic suspension allograft being developed for the management of symptomatic knee osteoarthritis (OA). The company said the filing marks a major re
- RTTNews · Apr 10, 10:00 AM EDTWeekly Buzz: MGNX Resumes LINNET; GSK Wins China Nod; FDA Okays Waters; NBIX Snaps Up SLNO(RTTNews) – This week's biotech landscape witnessed regulatory approvals across the U.S., Canada, and China, alongside the lifting of a clinical trial hold by the FDA, collaborations, acquisitions, discontinuations, and positive data readouts spanning multiple therapeutic areas.
- RTTNews · Apr 7, 6:59 AM EDTOrganogenesis Advances PuraPly AM, Stock Up(RTTNews) – Organogenesis Holdings Inc. (ORGO) announced it has completed a randomized controlled trial evaluating PuraPly AM in the management of non-healing diabetic foot ulcers.
- The Motley Fool · Feb 26, 6:07 PM ESTOrganogenesis (ORGO) Q4 2025 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Dec 24, 2:21 AM ESTOrganogenesis Initiates BLA Submission For ReNu In Knee Arthritis(RTTNews) – Organogenesis Holdings Inc. (ORGO) ,a regenerative medicine company announced that it has initiated the submission of a Biologics License Application or BLA to the US Food and Drug Administration or FDA for its lead amniotic suspension allograft, ReNu, for the managem
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Organogenesis Holdings Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.